{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:54:01Z","timestamp":1777085641986,"version":"3.51.4"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:italic>Mycobacterium kansasii<\/jats:italic>\n            is one of the most pathogenic and frequent nontuberculous mycobacteria isolated from humans. Patients with adverse drug reactions, resistant isolates, or suboptimal response require alternative treatment regimens. One hundred forty-eight consecutive clinical isolates of\n            <jats:italic>M. kansasii<\/jats:italic>\n            were tested for antimicrobial susceptibilities by the BACTEC 460 system (NCCLS) with two different inoculation protocols, one conventional and one alternative. In the alternative protocol, the inoculum 12B vial was incubated until the growth index was between 250 and 500. Four conventional antimycobacterial drugs (isoniazid, rifampin, streptomycin, and ethambutol) were studied with standard critical concentrations. The in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, and moxifloxacin were determined by measuring radiometric MICs. All isolates tested were identified as\n            <jats:italic>M. kansasii<\/jats:italic>\n            genotype I and were resistant to isoniazid at a concentration of 0.4 \u03bcg\/ml. One hundred twenty isolates (81.1%) were inhibited by 1 \u03bcg of isoniazid per ml. A high level of resistance to isoniazid (&gt;10 \u03bcg\/ml) was observed in six isolates (4.1%). Only five strains (3.4%) were resistant to rifampin (&gt;1 \u03bcg\/ml). All isolates studied were susceptible to streptomycin and ethambutol. The MICs at which 90% of the isolates were inhibited (in micrograms per milliliter) were as follows: linezolid, 1 (range, \u22640.25 to 2); telithromycin, &gt;16 (range, 4 to &gt;16); clarithromycin, 0.5 (range, \u22640.03 to 1); levofloxacin, 0.12 (range, 0.12 to 0.25); and moxifloxacin, 0.06 (range, \u22640.06 to 0.12). The susceptibility testing results with both inoculation protocols showed perfect correlation. In conclusion, all\n            <jats:italic>M. kansasii<\/jats:italic>\n            isolates showed decreased susceptibility to isoniazid, but resistance to rifampin was infrequent. Quinolones, especially moxifloxacin, were the most active antimicrobial agents tested, followed by clarithromycin. Linezolid also showed good activity against these microorganisms, but telithromycin's in vitro activity was poor.\n          <\/jats:p>","DOI":"10.1128\/aac.48.12.4562-4565.2004","type":"journal-article","created":{"date-parts":[[2004,11,24]],"date-time":"2004-11-24T03:00:46Z","timestamp":1101265246000},"page":"4562-4565","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":44,"title":["Comparative In Vitro Activities of Linezolid, Telithromycin, Clarithromycin, Levofloxacin, Moxifloxacin, and Four Conventional Antimycobacterial Drugs against\n            <i>Mycobacterium kansasii<\/i>"],"prefix":"10.1128","volume":"48","author":[{"given":"Fernando","family":"Alcaide","sequence":"first","affiliation":[{"name":"Departments of Microbiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Calatayud","sequence":"additional","affiliation":[{"name":"Departments of Microbiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Santi\u0301n","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogelio","family":"Marti\u0301n","sequence":"additional","affiliation":[{"name":"Departments of Microbiology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"10","volume":"135","year":"1987","unstructured":"Ahn, C. H., R. J. Wallace, Jr., L. C. Steele, and D. T. Murphy. 1987. Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. Am. Rev. Respir. Dis.135:10-16.","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.35.8.1959-1964.1997"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.6.1109"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.7326\/0003-4819-129-9-199811010-00004","volume":"129","year":"1998","unstructured":"Bloch, K. C., L. Zwerling, M. J. Pletcher, J. A. Hahn, J. L. Gerberding, S. M. Ostroff, D. J. Vugia, and A. L. Reingold. 1998. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann. Intern. Med.129:698-704.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1987"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1736-1738.2003"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/376987","volume":"37","year":"2003","unstructured":"Canueto-Quintero, J., F. J. Caballero-Granado, M. Herrero-Romero, A. Dominguez-Castellano, P. Martin-Rico, E. V. Verdu, D. S. Santamaria, R. C. Cerquera, M. Torres-Tortosa, et al. 2003. Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study. Clin. Infect. Dis.37:584-590.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_9_2","first-page":"921","volume":"45","year":"1996","unstructured":"Centers for Disease Control and Prevention. 1996. Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. Morb. Mortal. Wkly. Rep.45:921-925.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_10_2","first-page":"164","volume":"5","year":"1997","unstructured":"Chobot, S., J. Malis, H. Sebakova, M. Pelikan, O. Zatloukal, P. Palicka, and D. Kocurova. 1997. Endemic incidence of infections caused by Mycobacterium kansasii in the Karvina district in 1968-1995 (analysis of epidemiological data-review). Cent. Eur. J. Public Health5:164-173.","journal-title":"Cent. Eur. J. Public Health"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/thx.51.12.1248","volume":"51","year":"1996","unstructured":"Evans, S. A., A. Colville, A. J. Evans, A. J. Crisp, and I. D. A. Johnston. 1996. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis. Thorax51:1248-1252.","journal-title":"Thorax"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.3.393"},{"key":"e_1_3_2_13_2","first-page":"829","volume":"146","year":"1980","unstructured":"Good, R. C., and D. E. Snider, Jr. 1980. Isolation of nontuberculous mycobacteria in the United States, 1980. J. Infect. Dis.146:829-833.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/378742"},{"key":"e_1_3_2_15_2","unstructured":"Heifets L. B. 1991. Drug susceptibility in the chemotherapy of mycobacterial infection. CRC Press Inc. Boca Raton Fla."},{"key":"e_1_3_2_16_2","first-page":"127","year":"1996","unstructured":"Inderlied, C. B., and K. A. Nash. 1996. Antimycobacterial agents: in vitro susceptibility testing, spectra of activity, mechanisms of action and resistance, and assays for activity in biologic fluids, p. 127-175. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.","journal-title":"Antibiotics in laboratory medicine"},{"key":"e_1_3_2_17_2","first-page":"1149","year":"2003","unstructured":"Inderlied, C. B., and G. E. Pfyffer. 2003. Susceptibility test methods: mycobacteria, p. 1149-1177. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, D.C.","journal-title":"Manual of clinical microbiology"},{"key":"e_1_3_2_18_2","first-page":"19","volume":"58","year":"1999","unstructured":"Jacobs, M. R. 1999. Activity of quinolones against mycobacteria. Drugs.58(Suppl. 2):19-22.","journal-title":"Drugs."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/ajcp\/91.2.236","volume":"91","year":"1989","unstructured":"Jacobson, M. A., and W. M. Isenberg. 1989. Mycobacterium kansasii diffuse pulmonary infection in a patient with acquired immune deficiency syndrome: successful therapy with an antituberculous regimen. Am. J. Clin. Pathol.91:236-238.","journal-title":"Am. J. Clin. Pathol."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/136.2.349"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.5.760"},{"key":"e_1_3_2_22_2","unstructured":"National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria nocardiae and other aerobic actinomycetes; approved standard. Document M24-A. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.4.964-970.1999"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1128\/AAC.47.1.416-417.2003","volume":"47","year":"2003","unstructured":"Rodr\u00edguez D\u00edaz, J. C., M. L\u00f3pez, M. Ru\u00edz, and G. Royo. 2003. In vitro activity of new fluoroquinolones and linezolid against nontuberculous mycobacteria. Int. J. Antimicrob. Agents47:416-417.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_25_2","first-page":"673","volume":"7","year":"2003","unstructured":"Sant\u00edn, M., and F. Alcaide. 2003. Mycobacterium kansasii disease among patient infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy. Int. J. Tuberc. Lung Dis.7:673-677.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1017\/S095026880300150X","volume":"132","year":"2004","unstructured":"Sant\u00edn, M., F. Alcaide, M. A. Ben\u00edtez, A. Salazar, C. Ardanuy, D. Podzamczer, G. Ruf\u00ed, J. Dorca, R. Mart\u00edn, and F. Gudiol. 2004. Incidence and molecular typing of Mycobacterium kansasii in a defined geographical area in Catalonia, Spain. Epidemiol. Infect.132:425-432.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_27_2","unstructured":"Siddiqi S. H. 1995. BACTEC 460 TB system. Product and procedure manual revision D. Becton Dickinson Microbiology Systems Sparks Md."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0732-8893(85)90064-1","volume":"3","year":"1985","unstructured":"Steadham, J. E., S. K. Stall, and J. L. Simmank. 1985. Use of the BACTEC system for drug susceptibility testing of Mycobacterium tuberculosis,M. kansasii, and M. avium complex. Diagn. Microbiol. Infect. Dis.3:33-40.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.3.1240-1244.2003"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/clinids\/18.5.736","volume":"18","year":"1994","unstructured":"Wallace, R. J., Jr., D. Dunbar, B. A. Brown, G. Onyi, R. Dunlap, C. H. Ahn, and D. T. Murphy. 1994. Rifampin-resistant Mycobacterium kansasii. Clin. Infect. Dis.18:736-743.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.1.ed08-97"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.1.77"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/jac\/34.3.343","volume":"34","year":"1994","unstructured":"Yew, W. W., L. J. Piddock, M. S. Li, D. Lyon, C. Y. Chan, and A. F. Cheng. 1994. In-vitro activity of quinolones and macrolides against mycobacteria. J. Antimicrob. Chemother.34:343-351.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.1.119-125.2004"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.12.4562-4565.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.12.4562-4565.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:17:52Z","timestamp":1645467472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.12.4562-4565.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1128\/AAC.48.12.4562-4565.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.12.4562-4565.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]},"assertion":[{"value":"2004-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-08-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}